Windtree Therapeutics, Inc. Receivables

Receivables of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.


Highlights and Quick Summary

  • Receivables for the quarter ending September 29, 2014 was $22 Thousand (a -46.34% decrease compared to previous quarter)
  • Annual Receivables for 2013 was $67 Thousand
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of Windtree Therapeutics, Inc.

Most recent Receivablesof WINT including historical data for past 10 years.

Interactive Chart of Receivables of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2014 $0.02 $0.04
2013 $0.07 $0.07

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.